Guggenheim Reiterates Buy on Cogent Biosciences, Maintains $26 Price Target
Portfolio Pulse from richadhand@benzinga.com
Guggenheim analyst Charles Zhu reiterates a Buy rating on Cogent Biosciences (NASDAQ:COGT) and maintains a $26 price target.
June 13, 2023 | 12:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim analyst Charles Zhu reiterates a Buy rating on Cogent Biosciences and maintains a $26 price target.
The Guggenheim analyst's reiterated Buy rating and maintained price target of $26 for Cogent Biosciences indicates a positive outlook for the stock. This news is directly related to COGT and is important for investors as it provides a professional opinion on the stock's potential performance. The confidence in the analysis is high due to the analyst's expertise.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100